GO:0045818 negative regulation of glycogen catabolic process: Glycogenolysis Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045818 describes any process that stops, prevents, or reduces the breakdown of glycogen (glycogenolysis).
• This regulation is critical for maintaining blood glucose homeostasis, especially during fasting and between meals.
• Key inhibitory mechanisms include allosteric regulation by glucose-6-phosphate and ATP, and hormonal signaling via insulin.
• Dysregulation of glycogen catabolism is linked to metabolic disorders such as type 2 diabetes and glycogen storage diseases.
• Emerging evidence shows that neuronal and endocrine signals, including glucagon and pancreastatin, modulate hepatic glycogenolysis.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise dissection of regulatory nodes in glycogen catabolism.
Description
Glycogen is a branched polymer of glucose that serves as a critical energy reserve in liver and muscle. The breakdown of glycogen, termed glycogen catabolism or glycogenolysis, is tightly regulated to ensure glucose supply during fasting and exercise. The Gene Ontology term GO:0045818, negative regulation of glycogen catabolic process, encompasses any process that stops, prevents, or reduces the frequency, rate or extent of glycogen breakdown. This regulation is essential for preventing excessive glucose depletion and maintaining metabolic homeostasis. Researchers study this process to understand how cells balance energy storage and utilization, and how its dysregulation contributes to diseases such as diabetes and glycogen storage disorders. Recent work has highlighted the role of neuronal and hormonal signals in controlling hepatic glycogenolysis, underscoring the complexity of this regulatory network. Understanding GO:0045818 is therefore fundamental for metabolic research and therapeutic development.
negative regulation of glycogen catabolic process At A Glance
| GO ID | GO:0045818 |
|---|---|
| GO term | negative regulation of glycogen catabolic process |
| Ontology | biological_process |
| Synonym | negative regulation of glycogen breakdown, negative regulation of glycogen catabolism, negative regulation of glycogen degradation, negative regulation of glycogenolysis, inhibition of glycogen catabolic process |
| Major function | Inhibits the breakdown of glycogen, preserving energy stores and modulating glucose release |
| Related processes | Glycogen biosynthetic process, glucose homeostasis, insulin signaling, glucagon signaling |
| Key regulators | Insulin, glucose-6-phosphate, ATP, protein phosphatases, neuronal signals |
| Disease relevance | Type 2 diabetes, glycogen storage diseases, metabolic syndrome |
What Is GO:0045818?
GO:0045818, negative regulation of glycogen catabolic process, is defined as any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glycogen. In simpler terms, it includes all molecular events that inhibit glycogenolysis, the enzymatic degradation of glycogen into glucose-1-phosphate and glucose.
Why Is negative regulation of glycogen catabolic process Important in Cell Biology?
The negative regulation of glycogen catabolism is vital for preventing uncontrolled glucose release and maintaining metabolic balance. It ensures that glycogen stores are preserved when energy is abundant and mobilized only when needed. Dysregulation of this process can lead to hyperglycemia or hypoglycemia, contributing to metabolic disorders such as type 2 diabetes and glycogen storage diseases. Moreover, recent studies have revealed that neuronal inputs and endocrine factors like pancreastatin fine-tune hepatic glycogenolysis, highlighting the integrative nature of this regulation. Understanding GO:0045818 thus provides insights into whole-body glucose homeostasis and potential therapeutic targets.
• Maintains blood glucose levels during fasting and between meals by preventing excessive glycogen breakdown.
• Prevents wasteful depletion of glycogen stores when glucose is plentiful.
• Integrates hormonal signals (insulin, glucagon) to coordinate liver and muscle metabolism.
• Dysregulation is linked to insulin resistance and type 2 diabetes.
• Defects in glycogen catabolism regulation cause glycogen storage diseases.
• Neuronal regulation of glucagon secretion and gluconeogenesis influences glycogen catabolism.
• Pancreastatin, an endogenous peptide, regulates glucose homeostasis and may affect glycogenolysis.
• Exercise and cold exposure modulate glycogen metabolism, with implications for athletic performance.
• Muscle protein breakdown and glycogen catabolism are interconnected in periparturient dairy cows, a model for metabolic stress.
• Time-restricted feeding alters glycogen structural fragility and stability, affecting catabolism.
What Happens During negative regulation of glycogen catabolic process?
Hormonal Inhibition by Insulin
In simple terms: Insulin signals that glucose is abundant, so it tells the cell to stop breaking down glycogen.
Insulin, released after a meal, activates signaling cascades that lead to the inhibition of glycogenolysis. This includes activation of protein phosphatase 1 (PP1) and inhibition of glycogen phosphorylase, the rate-limiting enzyme of glycogen breakdown. Insulin also promotes glycogen synthesis, further reducing net glycogen catabolism.
Allosteric Regulation by Metabolites
In simple terms: Molecules like glucose-6-phosphate and ATP act as built-in brakes on glycogen breakdown.
Glucose-6-phosphate allosterically inhibits glycogen phosphorylase, while ATP inhibits phosphofructokinase-1, indirectly reducing the need for glycogenolysis. These metabolites signal energy sufficiency and prevent unnecessary glycogen degradation.
Neuronal and Endocrine Control
In simple terms: The brain and gut hormones can send signals to the liver to slow down glycogen breakdown.
Neuronal regulation of glucagon secretion and gluconeogenesis modulates hepatic glycogenolysis. For instance, hypothalamic signals can suppress glucagon release, thereby reducing glycogen catabolism. Additionally, pancreastatin, a peptide produced in the pancreas, regulates glucose homeostasis and may inhibit glycogenolysis under certain conditions.
Diurnal and Feeding-Related Regulation
In simple terms: The time of day and when you eat can change how stable glycogen is and how easily it breaks down.
Time-restricted feeding alters the structural fragility and stability of liver glycogen, affecting its catabolism. Diurnal variations in glycogen structure influence the accessibility of enzymes, thereby modulating the rate of glycogen breakdown.
Key Genes Involved in GO:0045818 negative regulation of glycogen catabolic process
The following genes and proteins are central to the negative regulation of glycogen catabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| INS | Encodes insulin, the primary hormone inhibiting glycogenolysis | Key regulator of glucose homeostasis; mutations cause diabetes |
| GCG | Encodes glucagon, which stimulates glycogenolysis; its inhibition reduces catabolism | Neuronal control of glucagon secretion affects glycogen breakdown |
| PPP1R3A | Regulatory subunit of protein phosphatase 1, targeting it to glycogen | Mediates insulin-induced inhibition of glycogenolysis |
| PYGL | Liver glycogen phosphorylase, rate-limiting enzyme of glycogenolysis | Allosterically inhibited by glucose-6-phosphate; mutations cause glycogen storage disease type VI |
| PYGM | Muscle glycogen phosphorylase | Regulated by AMP and ATP; mutations cause McArdle disease |
| G6PC | Glucose-6-phosphatase, catalyzes final step of glycogenolysis | Its expression is regulated to control glucose release |
| INSR | Insulin receptor, initiates signaling to inhibit glycogenolysis | Mutations cause insulin resistance and diabetes |
| AKT1 | Kinase that phosphorylates and inactivates glycogen synthase kinase-3 | Mediates insulin signaling to promote glycogen synthesis and inhibit breakdown |
| GSK3A | Glycogen synthase kinase-3 alpha, inhibits glycogen synthesis | Inhibition by insulin signaling reduces glycogen catabolism |
| PPP1CA | Catalytic subunit of protein phosphatase 1 | Dephosphorylates and inactivates glycogen phosphorylase |
| PRKAA1 | AMP-activated protein kinase catalytic subunit alpha-1 | Activates glycogenolysis when energy is low; its inhibition reduces catabolism |
| PRKAA2 | AMPK catalytic subunit alpha-2 | Similar to PRKAA1, regulates energy balance |
| FOXO1 | Transcription factor that promotes gluconeogenesis and glycogenolysis | Inhibited by insulin, reducing glycogen catabolism |
| CREB1 | Transcription factor activated by glucagon, promotes glycogenolysis | Its inhibition reduces glycogen breakdown |
| POMC | Pro-opiomelanocortin, precursor to melanocortin peptides in neurons | Neuronal POMC neurons regulate glucose homeostasis and glycogenolysis |
| NPY | Neuropeptide Y, co-expressed in AgRP neurons | Modulates feeding and glucose metabolism, affecting glycogen catabolism |
| CHGA | Chromogranin A, precursor of pancreastatin | Pancreastatin regulates glucose homeostasis and may inhibit glycogenolysis |
| SLC2A2 | GLUT2 glucose transporter in liver | Facilitates glucose uptake, indirectly influencing glycogen catabolism |
How Is negative regulation of glycogen catabolic process Regulated?
The negative regulation of glycogen catabolism is controlled by a network of hormonal, neuronal, and metabolic signals. Insulin is the primary inhibitor, acting through the PI3K/Akt pathway to activate protein phosphatase 1 and inhibit glycogen phosphorylase. Glucagon opposes insulin, but its secretion can be suppressed by neuronal inputs, thereby reducing glycogenolysis. Pancreastatin, a peptide derived from chromogranin A, has been shown to regulate glucose homeostasis and may inhibit glycogen breakdown under certain conditions. Additionally, allosteric effectors such as glucose-6-phosphate and ATP provide immediate feedback inhibition. Diurnal rhythms and feeding patterns also modulate glycogen structure and catabolism.
negative regulation of glycogen catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| INS | Type 2 diabetes, insulin resistance | Knockout of Ins in mice; overexpression in cell lines |
| PYGL | Glycogen storage disease type VI | Point mutation knock-in in HepG2 cells |
| PYGM | McArdle disease | Knockout in C2C12 myotubes |
| GCG | Hyperglucagonemia, diabetes | Knockout in pancreatic alpha cells |
| CHGA | Diabetes, metabolic syndrome | Overexpression of pancreastatin in hepatocytes |
Type 2 Diabetes and Insulin Resistance
In type 2 diabetes, impaired insulin signaling leads to reduced negative regulation of glycogen catabolism, contributing to excessive hepatic glucose output and hyperglycemia. Pancreastatin levels are altered in diabetes, further affecting glucose homeostasis.
Glycogen Storage Diseases
Mutations in genes encoding enzymes of glycogen metabolism, such as PYGL and PYGM, disrupt the balance between synthesis and breakdown, causing glycogen accumulation and exercise intolerance. Defects in regulatory pathways can also mimic these disorders.
Metabolic Syndrome and Obesity
Dysregulation of neuronal control of glucagon secretion and glycogenolysis contributes to metabolic syndrome. Hypothalamic circuits involving POMC and NPY neurons influence hepatic glucose production.
Exercise and Cold Stress
During exercise or cold exposure, glycogen catabolism is accelerated to provide energy. Negative regulation ensures that glycogen is not depleted prematurely, but in extreme conditions, this balance can be disturbed.
From negative regulation of glycogen catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X inhibit glycogen catabolism? | Knockout cell line (e.g., HepG2) followed by glycogen assay |
| Does a point mutation in PYGL affect allosteric inhibition? | Point mutation knock-in in HepG2 cells |
| Does overexpression of PPP1R3A reduce glycogenolysis? | Overexpression cell line (liver cells) |
| Does a tag on PYGL alter its localization? | Tagged knock-in (e.g., GFP-PYGL) in hepatocytes |
| Does neuronal POMC regulate hepatic glycogenolysis? | Conditional knockout mouse model |
| Does pancreastatin inhibit glycogen breakdown? | Knock-in of CHGA mutant in pancreatic cells |
How to Study the negative regulation of glycogen catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Glycogen assay | Cellular glycogen content | Screening for regulators of glycogenolysis |
| Phosphorylase activity assay | Enzyme activity | Testing allosteric inhibitors |
| Western blot | Protein phosphorylation and expression | Signaling pathway analysis |
| CRISPR knockout screen | Gene essentiality for glycogen regulation | Discovery of novel regulators |
| RNA-seq | Transcriptional changes | Identifying gene expression signatures |
| Proteomics | Protein abundance and modifications | Mapping regulatory networks |
| Live-cell imaging | Glycogen granule dynamics | Real-time visualization of catabolism |
Glycogen Content Assays
Colorimetric or fluorometric assays measure glycogen levels in cells or tissues. A decrease in glycogen content indicates increased catabolism, while an increase suggests inhibition.
Enzyme Activity Assays
Glycogen phosphorylase and phosphatase activities are measured using specific substrates. These assays determine the direct effects of regulatory proteins on enzyme function.
Western Blotting and Phosphorylation Analysis
Antibodies against phosphorylated forms of glycogen phosphorylase and its regulators reveal signaling changes. This method is used to assess insulin or glucagon signaling.
CRISPR Screening and Transcriptomics
Genome-wide CRISPR knockout screens coupled with RNA-seq identify genes that regulate glycogen catabolism. This approach uncovers novel regulators and pathways.
How CRISPR Can Be Used to Study GO:0045818 negative regulation of glycogen catabolic process
Knockout
CRISPR knockout of candidate genes (e.g., PYGL, PPP1R3A) in liver or muscle cell lines allows assessment of their role in glycogen catabolism. Loss of an inhibitor should increase glycogen breakdown, which can be quantified by glycogen assays.
Point Mutation
Introducing specific point mutations (e.g., in the allosteric site of PYGL) via CRISPR base editing or HDR enables study of how these mutations affect enzyme regulation and glycogenolysis.
Knock-in
Knock-in of tagged versions of regulatory proteins (e.g., GFP-PPP1R3A) allows visualization of their localization and interaction with glycogen particles in live cells.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of inhibitory proteins (e.g., PPP1R3A) can suppress glycogen catabolism, providing a gain-of-function model to study metabolic effects.
How EDITGENE Supports negative regulation of glycogen catabolic process Research
Researchers studying negative regulation of glycogen catabolic process-related genes often need to determine whether a candidate gene is causally involved in glycogen breakdown or merely correlated with metabolic changes. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic manipulation and functional validation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of glycogen catabolic process research.
Frequently Asked Questions About negative regulation of glycogen catabolic process
What is GO:0045818?
GO:0045818 is the Gene Ontology term for negative regulation of glycogen catabolic process, which includes any process that stops or reduces the breakdown of glycogen.
What genes are involved in negative regulation of glycogen catabolic process?
Key genes include INS, GCG, PPP1R3A, PYGL, PYGM, and CHGA, among others.
How does insulin inhibit glycogen breakdown?
Insulin activates protein phosphatase 1, which dephosphorylates and inactivates glycogen phosphorylase, thereby reducing glycogenolysis.
What diseases are associated with dysregulated glycogen catabolism?
Type 2 diabetes, glycogen storage diseases, and metabolic syndrome are linked to impaired regulation of glycogen breakdown.
What is the role of pancreastatin in glycogen metabolism?
Pancreastatin is an endogenous peptide that regulates glucose homeostasis and may inhibit glycogenolysis.
How does time-restricted feeding affect glycogen catabolism?
Time-restricted feeding alters the structural fragility and stability of liver glycogen, influencing its breakdown.
Can CRISPR be used to study glycogen catabolism?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise manipulation of genes involved in glycogen regulation.
What are the main methods to measure glycogen catabolism?
Glycogen content assays, enzyme activity assays, Western blotting, and CRISPR screens are commonly used.
How do neurons regulate glycogen breakdown?
Neuronal signals can suppress glucagon secretion, thereby reducing hepatic glycogenolysis.
What is the difference between glycogenolysis and glycogen catabolism?
Glycogenolysis specifically refers to the enzymatic breakdown of glycogen, while glycogen catabolism encompasses all pathways of glycogen degradation.
Conclusion
The negative regulation of glycogen catabolic process (GO:0045818) is a critical component of glucose homeostasis, integrating hormonal, neuronal, and metabolic signals to prevent excessive glycogen breakdown. Dysregulation of this process underlies several metabolic diseases, making it a key area of research. Advances in CRISPR technology and functional genomics provide powerful tools to dissect the regulatory networks involved. EDITGENE offers comprehensive services to support these investigations, from knockout and knock-in models to CRISPR screening and bioinformatics.
References
- 2. Thorens B. 2022. Neuronal regulation of glucagon secretion and gluconeogenesis.. J Diabetes Investig 13(4):599-607 PMID: 34989155
- 3. Nimmo M. 2004. Exercise in the cold.. J Sports Sci 22(10):898-915; discussion 915-6 PMID: 15768724
- 4. Sadri H et al.. 2023. Invited review: Muscle protein breakdown and its assessment in periparturient dairy cows.. J Dairy Sci 106(2):822-842 PMID: 36460512
- 5. Ma ZW et al.. 2024. Molecular exploration of the diurnal alteration of glycogen structural fragility and stability in time-restricted-feeding mouse liver.. Int J Biol Macromol 277(Pt 2):134225 PMID: 39074710
- 6. Kmieć Z. 2001. Cooperation of liver cells in health and disease.. Adv Anat Embryol Cell Biol 161:III-XIII, 1-151 PMID: 11729749
- 7. Muscogiuri G et al.. 2018. Water intake keeps type 2 diabetes away? Focus on copeptin.. Endocrine 62(2):292-298 PMID: 30027433
- 8. Valicherla GR et al.. 2013. Pancreastatin is an endogenous peptide that regulates glucose homeostasis.. Physiol Genomics 45(22):1060-71 PMID: 24064537
